Asia Beat: Grasping the nettle of traditional medicine regulation
This article was originally published in Scrip
There are some alarming inconsistencies in the testing of traditional herbal medicines produced in Asia, raising serious wider questions over the effective regulation of such products.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.